Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Giovanni Luca Gravina, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfon, Carles Domenech, Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Giovanni Luca Gravina, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfon, Carles Domenech, Claudio Festuccia
Abstract
Background: Glioblastoma multiforme (GBM) is the most malignant adult brain tumor. Current standard of care treatments have very limited efficacy, being the patients´ overall survival 14 months and the 2-year survival rate less than 10%. Therefore, the treatment of GBM is an urgent unmet clinical need.
Methods: The aim of this study was to investigate in vitro and in vivo the potential of ABTL0812, an oral anticancer compound currently in phase II clinical stage, as a novel therapy for GBM.
Results: We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. Additionally, ABTL0812 decreased GSCs neurosphere formation. GBM cells aggressiveness is associated with a trans-differentiation process towards a less differentiated phenotype known as proneural to mesenchymal transition (PMT). ABTL0812 was shown to revert PMT and induce cell differentiation to a less malignant phenotype in GBM cell lines and GSCs, and consequently reduced cell invasion. As previously shown in other cancer types, we demonstrated that the molecular mechanism of action of ABTL0812 in glioblastoma involves the inhibition of Akt/mTORC1 axis by overexpression of TRIB3, and the activation of endoplasmic reticulum (ER) stress/unfolded protein response (UPR). Both actions converge to induce autophagy-mediated cell death. ABTL0812 anticancer efficacy was studied in vivo using subcutaneous and orthotopic intra-brain xenograft tumor models. We demonstrated that ABTL0812 impairs tumor growth and increases disease-free survival and overall survival of mice. Furthermore, the histological analysis of tumors indicated that ABTL0812 decreases angiogenesis. Finally, we investigated the combination of ABTL0812 with the standard of care treatments for GBM radiotherapy and temozolomide in an orthotopic model, detecting that ABTL0812 potentiates the efficacy of both treatments and that the strongest effect is obtained with the triple combination of ABTL0812+radiotherapy+temozolomide.
Conclusions: Overall, the present study demonstrated the anticancer efficacy of ABTL0812 as single agent and in combination with the GBM standard of care treatments in models of glioblastoma and supports the clinical investigation of ABTL0812 as a potential novel therapy for this aggressive brain tumor type.
Keywords: ABTL0812; Akt; ER stress; TRIB3; UPR; autophagy; glioblastoma; mTOR.
Conflict of interest statement
HP-M, MY-V, JA, and CD are employees of Ability Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Copyright © 2022 Mancini, Colapietro, Cristiano, Rossetti, Mattei, Gravina, Perez-Montoyo, Yeste-Velasco, Alfon, Domenech and Festuccia.
Figures
References
- Huang Q, Li F, Chen Y, Hong F, Wang H, Chen J. Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a surveillance, epidemiology, and end results (SEER) analysis from 2004 to 2015. Br J Neurosurg (2019) 12:1–7. doi: 10.1080/02688697.2019.1699903
- Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther (2015) 152:63–82. doi: 10.1016/j.pharmthera.2015.05.005
- Katsigiannis S, Krischek B, Barleanu S, Grau S, Galldiks N, Timmer M, et al. . Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma. Radiat Oncol (2019) 14:73. doi: 10.1186/s13014-019-1272-6
- Sonoda Y. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Int J Clin Oncol (2020) 25:1004–09. doi: 10.1007/s10147-020-01628-7
- Saito N, Hirai N, Aoki K, Sato S, Suzuki R, Hiramoto Y, et al. . Genetic and lineage classification of glioma-initiating cells identifies a clinically relevant glioblastoma model. Cancers (Basel) (2019) 11:1564–79. doi: 10.3390/cancers11101564
- Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: Phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci (2019) 20(11):2746. doi: 10.3390/ijms20112746
- Iser IC, Pereira MB, Lenz G, Wink MR. The epithelial-to-Mesenchymal transition-like process in glioblastoma: An updated systematic review and in silico investigation. Med Res Rev (2017) 37:271–313. doi: 10.1002/med.21408
- Tejero R, Huang Y, Katsyv I, Kluge M, Lin JY, Tome-Garcia J, et al. . Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine (2019) 42:252–69. doi: 10.1016/j.ebiom.2019.03.064
- Zhao K, Cui X, Wang Q, Fang C, Tan Y, Wang Y, et al. . RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner. Cell Death Dis (2019) 10:877. doi: 10.1038/s41419-019-2108-x
- Stanzani E, Martínez-Soler F, Mateos TM, Vidal N, Villanueva A, Pujana MA, et al. . Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program. Oncotarget (2017) 8:73640–53. doi: 10.18632/oncotarget.18363
- Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velázquez Vega JE, et al. . Human mesenchymal glioblastomas are characterized by an increased immune cell presence compared to proneural and classical tumors. Oncoimmunology (2019) 8:e1655360. doi: 10.1080/2162402X.2019.1655360
- Guardia GDA, Correa BR, Araujo PR, Qiao M, Burns S, Penalva LOF, et al. . Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles. NPJ Genom Med (2020) 5:2. doi: 10.1038/s41525-019-0108-5
- Erazo T, Lorente M, López-Plana A, Munoz-Guardiola P, Ferńandez-Nogueira P, García-Martínez JA, et al. . The new antitumor drug ABTL0812 inhibits the Akt/mTORC1 axis by upregulating tribbles-3 pseudokinase. Clin Cancer Res (2016) 22:2508–19. doi: 10.1158/1078-0432.CCR-15-1808
- Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, et al. . The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy (2020) 17:1349–66. doi: 10.1080/15548627.2020.1761651
- Felip I, Moiola CP, Megino-Luque C, Lopez-Gil C, Cabrera S, Solé-Sánchez S, et al. . Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecol Oncol (2019) 153(2):425–35. doi: 10.1016/j.ygyno.2019.03.002
- López-Plana A, Fernández-Nogueira P, Muñoz-Guardiola P, Solé-Sánchez S, Megías-Roda E, Pérez-Montoyo H, et al. . The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. Int J Cancer (2020) 147(4):1163–79. doi: 10.1002/ijc.32865
- París-Coderch L, Soriano A, Jiménez C, Erazo T, Muñoz-Guardiola P, Masanas M, et al. . The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis. Cell Death Dis (2020) 11(9):773. doi: 10.1038/s41419-020-02986-w
- Polonio-Alcalá E, Solé-Sánchez S, Muñoz-Guardiola P, Megías-Roda E, Perez-Montoyo H, Yeste-Velasco M, et al. . ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. Cancer Commun (Lond) (2022) 42(6):567–71. doi: 10.1002/cac2.12282
- Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, et al. . A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. Eur J Cancer (2021) 146:87–94. doi: 10.1016/j.ejca.2020.12.019
- Leary A, Estévez-García P, Sabatier R, Estévez-García P, Sabatier R, Fariñas-Madrid L, Pérez-Fidalgo JA, Romeo M, et al. . Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer. Ann Oncol (2020) 31(Suppl 4):S639–40. doi: 10.1016/j.annonc.2020.08.1003
- Bosch-Barrera J, Moran T, Estévez-García P, Martin-Martorell P, Sabatier R, Nadal E, et al. . Phase 2 of pro-autophagic drug ABTL0812 in combination with first-line paclitaxel and carboplatin in IIIb/IV squamous NSCLC. J Thor Oncol (2021) 16(3):S130–1. doi: 10.1016/j.jtho.2021.01.202
- Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, et al. . Molecular definitions of autophagy and related processes. EMBO J (2017) 40:280–93. doi: 10.15252/embj.201796697
- Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell (2010) 20:243–51. doi: 10.1016/j.molcel.2010.09.023
- Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol (2018) 4:e892. doi: 10.1038/s41556-018-0042-2
- Liu B, Wen X, Cheng Y. Survival or death: Disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis (2013) 18:1959–81. doi: 10.1038/cddis.2013.422
- Byun S, Lee E, Lee KW. Therapeutic implications of autophagy inducers in immunological disorders, infection, and cancer. Int J Mol Sci (2017) 119:2460–9. doi: 10.3390/ijms18091959
- Bahrami A, Khazaei M, Hasanzadeh M, ShahidSales S, Joudi Mashhad M, Farazestanian M, et al. . Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer: Rational and progress. J Cell Biochem (2018) 119:2460–9. doi: 10.1002/jcb.25950
- Marquard FE. Jücker m PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol (2020) 172:113729. doi: 10.1016/j.bcp.2019.113729
- Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer (2020) 11(3):511–8. doi: 10.1111/1759-7714.13328
- Roncolato F, Lindemann K, Willson ML, Martyn J. Mileshkin L.PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev (2019) 10:CD012160. doi: 10.1002/14651858.CD012160.pub2
- Li X, Wu C, Chen N, Gu H, Yen A, Cao L, et al. . PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget (2016) 7(22):33440–50. doi: 10.18632/oncotarget.7961
- Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, et al. . An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology (2012) 14:184–91. doi: 10.1093/neuonc/nor207
- Mendiburu-Elicabe M, Gil-Ranedo J, Izquierdo M. Efficacy of rapamycin against glioblastoma cancer stem cells. Clin Transl Oncol (2014) 16:495–502. doi: 10.1007/s12094-013-1109-y
- Gravina GL, Mancini A, Colapietro A, Delle Monache S, Sferra R, Pompili S, et al. . The brain penetrating and dual TORC1/TORC2 inhibitor, RES529, elicits anti-glioma activity and enhances the therapeutic effects of anti-angiogenetic compounds in preclinical murine models. Cancers (Basel) (2019) 11:1604–20. doi: 10.3390/cancers11101604
- Laks DR, Crisman TJ, Shih MY, Mottahedeh J, Gao F, Sperry J, et al. . Large-Scale assessment of the gliomasphere model system. Neuro Oncol (2016) 18:1367–78. doi: 10.1093/neuonc/now045
- Gravina GL, Mancini A, Colapietro A, Delle Monache S, Sferra R, Vitale F, et al. . The small molecule ephrin receptor inhibitor, GLPG1790, reduces renewal capabilities of cancer stem cells, showing anti-tumour efficacy on preclinical glioblastoma models. Cancers (2019) 11:359. doi: 10.3390/cancers11030359
- Colapietro A, Mancini A, Vitale F, Martellucci S, Angelucci A, Llorens S, et al. . Crocetin extracted from saffron shows antitumor effects in models of human glioblastoma. Int J Mol Sci (2020) 21(2):423. doi: 10.3390/ijms21020423
- Gravina GL, Marampon F, Sherris D, Vittorini F, Di Cesare E, Tombolini V, et al. . Torc1/Torc2 inhibitor, palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Prostate (2014) 74:852–68. doi: 10.1002/pros.22804
- Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, et al. . UniPR1331, a small molecule targeting eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget (2018) 9:24347–63. doi: 10.18632/oncotarget.25272
- Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, et al. . Bologna Bicalutamide increases phospho-akt levels through Her2 in patients with prostate cancer. M. Endocr Relat Cancer (2007) 14(3):601–11. doi: 10.1677/ERC-07-0118
- Takiyama A, Teramoto T, Suzuki H, Yamashiro K, Tanaka S. Persistent homology index as a robust quantitative measure of immunohistochemical scoring. Sci Rep (2017) 7(1):14002. doi: 10.1038/s41598-017-14392-y
- Guo M, Goudarzi KM, Abedi S, Pieber M, Sjöberg E, Behnan J, et al. . SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma. Oncogene (2021) 40(32):5066–80. doi: 10.1038/s41388-021-01825-2
- Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry (2021) 92(10):1103–11. doi: 10.1136/jnnp-2020-325334
- Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. . Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer (2022) 21(1):39. doi: 10.1186/s12943-022-01513-z
- Papavassiliou KA, Papavassiliou AG. The bumpy road towards mTOR inhibition in glioblastoma: Quo vadis? Biomedicines (2021) 9(12):1809. doi: 10.3390/biomedicines9121809
- Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens JA, et al. . Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro Oncol (2019) 21(2):252–63. doi: 10.1093/neuonc/noy150
- Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, et al. . PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res (2008) 14(12):3993–4001. doi: 10.1158/1078-0432.CCR-07-4152
- Shi P, Xu J, Xia F, Wang Y, Ren J, Liang P, et al. . MOXD1 knockdown suppresses the proliferation and tumor growth of glioblastoma cells via ER stress-inducing apoptosis. Cell Death Discovery (2022) 8(1):174. doi: 10.1038/s41420-022-00976-9
- Peñaranda-Fajardo NM, Meijer C, Liang Y, Dijkstra BM, Aguirre-Gamboa R, den Dunnen WFA, et al. . ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. Cell Death Dis (2019) 10(10):690. doi: 10.1038/s41419-019-1934-1
- Shi P, Zhang Z, Xu J, Zhang L. Cui h endoplasmic reticulum stress−induced cell death as a potential mechanism for targeted therapy in glioblastoma (Review). Int J Oncol (2021) 59(2):60. doi: 10.3892/ijo.2021.5240
Source: PubMed